Ireland· IE-PA-EU/1/97/047/009
BeneFIX 1500 IU powder and solvent for solution for injection
A nonacog alfa (rekombinanter blutgerinnungsfaktor ix) product containing nonacog alfa, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nonacog alfa (rekombinanter blutgerinnungsfaktor ix) is registered in 2 of 19 countries.
Countries holding a registration under ATC B02BD09 (nonacog alfa (rekombinanter blutgerinnungsfaktor ix)), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Nonacog alfa (rekombinanter blutgerinnungsfaktor ix) · ATC B02BD09
2 / 19 countries
- Belgiumprice
- Ireland
The record
At a glance
HPRA (Ireland)- Active substance
- Nonacog alfa
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- B02BD09
- ATC class
- Nonacog alfa (rekombinanter Blutgerinnungsfaktor IX)
- Defined daily dose
- 800 E, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/97/047/009
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nonacog alfa (rekombinanter blutgerinnungsfaktor ix) in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBenefixPfizer Europe MA EEIG
- BelgiumBeneFIX 1000 IUPfizer Europe MA
- SwedenBeneFIX 1000 IE Pulver och vätska till injektionsvätska, lösningPfizer Europe MA EEIG
- CzechiaBENEFIXPfizer Europe MA EEIG, Bruxelles
- IcelandBeneFIXPfizer Europe MA EEIG*
- PolandBeneFixPfizer Europe MA EEIG
- NetherlandsBeneFIX 1000 IE, poeder voor injectievloeistofPfizer Europe MA EEIG
- United KingdomBeneFIX 1,000unit powder and solvent for solution for infusion vialsPfizer Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Benefix, Rixubis
- Liechtenstein · Benefix, Rixubis
- Norway · Benefix, Rixubis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/64410f31-5088-4a7e-8528-f3f96d9eb772 GET /v1/drugs/64410f31-5088-4a7e-8528-f3f96d9eb772?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"B02BD",
"B02BD09"
],
"strength": null,
"pa_number": "EU/1/97/047/009",
"substances": [
"Nonacog alfa"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "22/03/2017",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nonacog alfa (rekombinanter blutgerinnungsfaktor ix).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.